GlassScriptPhysician profile
Dennis T Jordanides
NPI 1285638031
$1,595.06
in general payments reported to CMS, 2019-2025
28 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $167 · 2021: $430 · 2022: $129 · 2023: $128 · 2024: $278 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $322.95 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $230.50 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $97.33 | 2019-2023 | |
| Amgen INC. | $86.00 | 2019-2024 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.81 | 2020-2022 | |
| Abbvie INC. | $63.17 | 2021 | |
| Sonex Health, INC. | $62.71 | 2025 | Sx-One Microknife |
| Daiichi Sankyo INC. | $59.55 | 2019-2021 | |
| Exact Sciences Corporation | $55.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Paratek Pharmaceuticals, INC. | $53.93 | 2021-2024 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $53.12 | 2023-2024 | Quviviq |
| Lucid Diagnostics INC. | $45.24 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $42.63 | 2020-2025 | Airsupra |
| Astellas Pharma US INC | $34.94 | 2024 | Veozah |
| Dexcom, INC. | $34.44 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $32.98 | 2021 | |
| Cleerly, INC. | $29.19 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Allergan, INC. | $28.89 | 2019-2020 | |
| Invivyd INC | $28.33 | 2025 | Pemgarda |
| Amarin Pharma, INC. | $24.86 | 2019 | |
| Sumitomo Pharma America, INC. | $23.74 | 2024 | Gemtesa |
| Azurity Pharmaceuticals, INC. | $18.51 | 2024 | Horizant |
| Electromed, INC. | $17.32 | 2025 | Smartvest |
| Irhythm Technologies, INC. | $14.90 | 2024 | Zio Monitor, Zio Xt Patch |
| E.R. Squibb & Sons, L.L.C. | $14.23 | 2023 | Eliquis |
| Arbor Pharmaceuticals, INC. | $12.52 | 2019 | |
| Glaxosmithkline, LLC. | $12.38 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Jordanides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.